Biopharma hacking resistant cancer stem cells


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9


Unfathomable Problem

How We Do It

Most cancers are resistant to chemotherapy from the very start. Consequently, many drugs are prescribed at ultra-high dosages to combat that resistance.

This quickly leads to a balancing act between:

  • Effective chemotherapy
  • And killing the patient

Our solution is a FDA approved drug that eliminates resistance in cancer stem cells.

Traction & Accomplishments

  • Proof of concept
  • Pre-clinical validation
  • Retrospective Clinical Data

We will initiate Phase 1B clinical trials in Q4 2019.

We will seek FDA approval through the abbreviated and/or supplemental new drug application (ANDA or sNDA) regulatory path.

We have identified mulitiple partners for commercialization.

And we have 4 patents pending.

Meet The Team

  • Was previously a postdoctoral fellow at the UCSF Cancer Center under the mentorship of the legendary cancer biologist, Dr. J. Michael Bishop, Chancellor Emeritus of UCSF and co-recipient of the Nobel Prize in Physiology or Medicine in 1989.
  • Vikash obtained his Ph.D. from UT Southwestern Medical Center at Dallas, where he studied role of telomerase in cancer stem cells under the mentorship of Jerry Shay and Woodring Wright.
  • Prior to his graduate career, Vikash spent many years conducting cancer research at several companies, such as:
  • Cell Genesis - Tularik - Genentech - Dendreon - Geron
  • During his career he made several discoveries, some of which have translated into cancer therapies.

  • Dr. Caughey is a Professor Emeritus at UCSF Medical Center where his lab conducted research for nearly 40 years in understanding how protein-cleaving enzymes of mast cells, white blood cells, and cells lining the airway contribute to:
  • Initiation of Cancer
  • Inflammation
  • Host defense
  • Tissue remodeling and barrier function in the lung
  • These studies relate to clinical problems in cancer, asthma, cystic fibrosis, lung transplantation and pneumonia.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.